Scholarlink

<p>This single-center subgroup analysis of a prospective trial (NCT04571086) at University Hospital Essen investigated tumor uptake and detection rates of [<sup>68</sup>Ga]Ga-FAPI-46- versus [<sup>18</sup>F]FDG PET in triple-negative breast cancer (TNBC) patients undergoing initial or follow-up staging. Lesions were recorded across anatomical regions, with detection efficacy, uptake values, tumor-to-liver ratios, and tumor volumes assessed. 22 patients were included (initial- <i>n</i> = 10, follow-up staging <i>n</i> = 12). No significant difference in region-based detection rates was observed between [<sup>18</sup>F]FDG- (93%, 53/57 regions) and [<sup>68</sup>Ga]Ga-FAPI-46 PET (93%, 53/57 regions) (McNemar <i>p</i> = 1.0). Three patients (25%) at follow-up staging showed an average tumor SUV<sub>mean</sub> ≥5 on [<sup>68</sup>Ga]Ga-FAPI-46 PET; 2/3 showed SUV<sub>max</sub> &gt;10 in most lesions. Mean tumor volume was higher for [<sup>68</sup>Ga]Ga-FAPI-46, though not statistically significant at initial- (50.1 ± 120.8 mL vs. 11.9 ± 18.5 mL) and follow-up staging (102.2 ± 122.3 mL vs. 79.0 ± 90.4 mL). [⁶⁸Ga]Ga-FAPI-46 PET demonstrated comparable detection in TNBC; high tumor uptake in a subset, supporting its theranostic potential.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Diagnostic value of [68Ga]Ga-FAPI-46 PET in comparison to [18F]FDG PET in triple-negative breast cancer and potential for theranostic application

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年8月3日

查看全文
  • Alina Toni Küper,
  • Ieva Ciuciulkaite,
  • Anja Welt,
  • Sofia Carrilho Vaz,
  • Ilektra Antonia Mavroeidi,
  • Rainer Hamacher,
  • Tristan Demmert,
  • Kim Magaly Pabst,
  • Alexandros Moraitis,
  • Loic Djaileb,
  • Robert Seifert,
  • Lale Umutlu,
  • Martin Schuler,
  • Ken Herrmann,
  • Wolfgang Peter Fendler,
  • Sherko Kümmel,
  • David Kersting

摘要

This single-center subgroup analysis of a prospective trial (NCT04571086) at University Hospital Essen investigated tumor uptake and detection rates of [68Ga]Ga-FAPI-46- versus [18F]FDG PET in triple-negative breast cancer (TNBC) patients undergoing initial or follow-up staging. Lesions were recorded across anatomical regions, with detection efficacy, uptake values, tumor-to-liver ratios, and tumor volumes assessed. 22 patients were included (initial- n = 10, follow-up staging n = 12). No significant difference in region-based detection rates was observed between [18F]FDG- (93%, 53/57 regions) and [68Ga]Ga-FAPI-46 PET (93%, 53/57 regions) (McNemar p = 1.0). Three patients (25%) at follow-up staging showed an average tumor SUVmean ≥5 on [68Ga]Ga-FAPI-46 PET; 2/3 showed SUVmax >10 in most lesions. Mean tumor volume was higher for [68Ga]Ga-FAPI-46, though not statistically significant at initial- (50.1 ± 120.8 mL vs. 11.9 ± 18.5 mL) and follow-up staging (102.2 ± 122.3 mL vs. 79.0 ± 90.4 mL). [⁶⁸Ga]Ga-FAPI-46 PET demonstrated comparable detection in TNBC; high tumor uptake in a subset, supporting its theranostic potential.